AYTU

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.08
Percentage change 3.67	%

Peers: AUPH CYTK BHC AMRX INVA IRWD HRTX GERN AXDX XOMA

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.71	Insider Own	12.52%	Shs Outstand	6.17M	Perf Week	10.78%
Market Cap	13.94M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	14.58%	Shs Float	5.40M	Perf Month	26.97%
Enterprise Value	18.29M	PEG	-	EPS next Q	-0.02	Inst Own	39.71%	Short Float	11.57%	Perf Quarter	88.33%
Income	1.64M	P/S	0.20	EPS this Y	108.04%	Inst Trans	-1.28%	Short Ratio	0.45	Perf Half Y	47.39%
Sales	69.22M	P/B	0.40	EPS next Y	-167.39%	ROA	0.85%	Short Interest	0.62M	Perf YTD	32.94%
Book/sh	5.66	P/C	0.77	EPS next 5Y	-	ROE	3.29%	52W High	2.96 -23.65%	Perf Year	-20.98%
Cash/sh	2.95	P/FCF	-	EPS past 3/5Y	65.49% 66.68%	ROIC	3.61%	52W Low	0.95 137.89%	Perf 3Y	-78.24%
Dividend Est.	-	EV/EBITDA	2.61	Sales past 3/5Y	7.27% 61.73%	Gross Margin	62.72%	Volatility	8.73% 9.92%	Perf 5Y	-99.24%
Dividend TTM	-	EV/Sales	0.26	EPS Y/Y TTM	107.53%	Oper. Margin	0.53%	ATR (14)	0.17	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.87	Sales Y/Y TTM	-26.17%	Profit Margin	2.37%	RSI (14)	66.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.03	EPS Q/Q	140.48%	SMA20	14.90%	Beta	0.13	Target Price	10.50
Payout	-	Debt/Eq	0.65	Sales Q/Q	2.55%	SMA50	33.03%	Rel Volume	0.14	Prev Close	2.18
Employees	102	LT Debt/Eq	0.30	Earnings	May 14 AMC	SMA200	34.92%	Avg Volume	1.40M	Price	2.26
IPO	Sep 24, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	217.65% 34.30%	Trades		Volume	190,105	Change	3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Today	Initiated	Lake Street	Buy	$8
Jun-30-25	Initiated	Ascendiant Capital Markets	Buy	$12
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight	$11
May-29-20	Initiated	H.C. Wainwright	Buy	$3

Jun-25-25 08:00AM	Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM) (ACCESSWIRE) +5.39%
Jun-23-25 08:00AM	Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM) (ACCESSWIRE)
Jun-09-25 04:30PM	Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan (ACCESSWIRE) +5.50%
07:30AM	Aytu BioPharma to commercialise Exxua for MDD in the US (Pharmaceutical Technology)
Jun-06-25 08:01AM	Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock (ACCESSWIRE) +34.23%
08:00AM	Loading…
08:00AM	Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States (ACCESSWIRE)
May-15-25 03:17AM	Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +91.85%
May-14-25 04:05PM	Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-07-25 04:15PM	Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025 (ACCESSWIRE)
Apr-21-25 04:05PM	Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025 (ACCESSWIRE)
Feb-13-25 08:00AM	Aytu BioPharma Inc (AYTU) Q2 2025 Earnings Call Highlights: Strong Cash Position and Strategic ... (GuruFocus.com)
Feb-12-25 04:03PM	Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results (ACCESSWIRE)
Feb-05-25 05:50PM	Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025 (ACCESSWIRE) +6.29%
Jan-06-25 09:00AM	Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 (ACCESSWIRE) +5.07%
Dec-05-24 06:32AM	Aytu BioPharma Proposes Settlement in Shareholder Lawsuit (TipRanks)
11:45PM	Loading…
Dec-03-24 11:45PM	Aytu BioPharma Disclosure Notification (ACCESSWIRE)
Nov-22-24 09:00AM	Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) (ACCESSWIRE) +8.08%
Nov-14-24 02:16AM	Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Historic Quarter with Positive ... (GuruFocus.com) -11.17%
Nov-13-24 04:05PM	Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results (ACCESSWIRE)
Nov-06-24 05:20PM	Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024 (ACCESSWIRE)
Oct-14-24 04:15PM	Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE)
Oct-01-24 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada (ACCESSWIRE)
Sep-27-24 07:40AM	Q4 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents) -17.16%
Sep-26-24 04:15PM	Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results (ACCESSWIRE) +17.24%
Sep-19-24 05:30PM	Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024 (ACCESSWIRE)
Aug-08-24 05:20PM	Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024 (ACCESSWIRE)
Aug-06-24 08:00AM	Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations (ACCESSWIRE)
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jun-18-24 08:00AM	Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms (ACCESSWIRE)
06:44PM	Loading…
May-29-24 06:44PM	Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 (Newsfile)
May-23-24 09:00AM	Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (ACCESSWIRE)
May-16-24 09:53AM	Q3 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Aytu BioPharma Inc (AYTU) Q3 2024 Earnings Call Transcript Highlights: Strategic Gains Amidst ... (GuruFocus.com)
May-15-24 08:54PM	AYTU Stock Earnings: Aytu BioPharma Beats EPS, Beats Revenue for Q3 2024 (InvestorPlace) -7.83%
04:05PM	Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results (ACCESSWIRE)
May-08-24 04:15PM	Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024 (ACCESSWIRE)
Apr-03-24 09:00AM	Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM	Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Feb-16-24 08:27AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2024 Earnings Call Transcript (Insider Monkey)
Feb-15-24 05:49AM	Q2 2024 Aytu Biopharma Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 04:05PM	Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter (ACCESSWIRE) +5.35%
Feb-07-24 04:15PM	Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024 (ACCESSWIRE)
Jan-23-24 09:00AM	Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024 (ACCESSWIRE)
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire)
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire)
Nov-30-23 08:00AM	Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023 (ACCESSWIRE)
Nov-15-23 09:44AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript (Insider Monkey) -22.11%
Nov-14-23 04:05PM	Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results (ACCESSWIRE) +10.11%
Nov-08-23 08:30AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year (ACCESSWIRE)
Nov-07-23 04:15PM	Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023 (ACCESSWIRE) +5.14%
Oct-26-23 08:00AM	Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.82%
Oct-09-23 04:15PM	Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023 (ACCESSWIRE) -8.59%
Sep-28-23 08:18AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2023 Earnings Call Transcript (Insider Monkey) +39.06%
Sep-27-23 04:20PM	Aytu BioPharma Reports Record Revenues, Record Prescriptions, and Highest Adjusted EBITDA in Company History for the Fourth Quarter of Fiscal Year 2023 (ACCESSWIRE) +16.36%
Sep-21-23 08:25PM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023 (ACCESSWIRE)
Sep-13-23 08:00AM	Aytu BioPharma to Present at LD Micro Main Event XVI Conference (ACCESSWIRE)
Aug-09-23 10:26AM	UPS downgraded, Eli Lilly upgraded: Wall Street's top analyst calls (The Fly) +10.30%
07:43AM	Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Jul-31-23 08:00AM	Aytu BioPharma Announces Exclusive Agreement with Medomie Pharma Ltd. to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Israel and the Palestinian Authority (ACCESSWIRE)
Jul-10-23 08:00AM	Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement (ACCESSWIRE) +5.36%
Jun-14-23 08:00AM	Aytu to Participate in the Maxim Group Virtual Healthcare Conference (ACCESSWIRE)
Jun-13-23 01:45PM	Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-Market (ACCESSWIRE) +6.59%
Jun-09-23 08:00AM	Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director (ACCESSWIRE)
May-16-23 11:51AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 04:25PM	AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates (InvestorPlace) -13.21%
04:05PM	Aytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results (ACCESSWIRE)
May-04-23 04:30PM	Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023 (ACCESSWIRE)
May-01-23 08:00AM	Aytu BioPharma Subleases a Portion of Its Manufacturing Facility (ACCESSWIRE)
Apr-27-23 08:00AM	Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer (ACCESSWIRE)
Mar-06-23 09:55AM	Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Feb-23-23 04:33PM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript (Insider Monkey) -5.78%
Feb-21-23 04:10PM	Aytu BioPharma Reports Second Quarter of Fiscal Year 2023 (ACCESSWIRE) -5.78%
03:00PM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023 (ACCESSWIRE)
Feb-14-23 08:00AM	Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results (ACCESSWIRE)
Feb-07-23 08:00AM	Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023 (ACCESSWIRE)
Feb-06-23 10:57AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-25-23 08:00AM	Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance (ACCESSWIRE) -6.46%
Jan-24-23 08:00AM	Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31 (ACCESSWIRE)
Jan-10-23 08:00AM	Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients (ACCESSWIRE)
Jan-05-23 04:01PM	Aytu BioPharma Announces 1-for-20 Reverse Stock Split (ACCESSWIRE) +7.28% -10.27%
Dec-29-22 06:01AM	Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript (Insider Monkey)
Nov-30-22 08:00AM	Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect (ACCESSWIRE)
Nov-22-22 04:05PM	Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (ACCESSWIRE) -13.51%
Nov-17-22 08:58AM	US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results (Simply Wall St.)
08:00AM	Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row (ACCESSWIRE)
Nov-16-22 08:00AM	Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso (ACCESSWIRE) +12.58%
05:59AM	Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
Nov-14-22 04:05PM	Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023 (ACCESSWIRE)
Nov-07-22 04:01PM	Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022 (ACCESSWIRE)
Oct-25-22 08:00AM	Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan (ACCESSWIRE) +6.72%
Oct-13-22 10:57AM	Aytu BioPharma Announces Strategic Shift, Indefinite Suspension of Clinical Development Programs (Benzinga)
08:00AM	Aytu BioPharma Announces Strategic Shift to Focus on Commercial Operations and Indefinite Suspension of Clinical Development Programs (ACCESSWIRE)
Oct-05-22 08:00AM	Aytu BioPharma Announces Continuing Availability of ADHD Medication Adzenys XR-ODT(R) in Response to Reported Generic Adderall(R) XR Supply Disruptions (ACCESSWIRE) -5.18%
Sep-27-22 04:30PM	Edited Transcript of AYTU.OQ earnings conference call or presentation 27-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Aytu BioPharma Reports Record Fourth Quarter and Fiscal Year 2022 Revenue (ACCESSWIRE)
Sep-20-22 08:00AM	Aytu BioPharma to Report Fourth Quarter and Fiscal 2022 Financial Results on September 27, 2022 (ACCESSWIRE)
Sep-14-22 08:00AM	Aytu BioPharma Announces Addition of Fourth Patent License for AR101/Enzastaurin (ACCESSWIRE)

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Disbrow Jarrett	Chief Business Officer	Jun 09 '25	Buy	1.50	16,666	24,999	29,462	Jun 10 03:06 PM
Disbrow Joshua R.	Chief Executive Officer	Jun 09 '25	Buy	1.50	66,666	99,999	153,257	Jun 10 03:04 PM
Disbrow Joshua R.	Chief Executive Officer	Feb 28 '25	Buy	1.30	15,000	19,500	86,591	Mar 03 01:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aytu BioPharma Inc

Upgrade your FINVIZ experience